Cefodizime (THR-221) in the field of internal medicine

Yoshio Kobayashi, Hiroshi Kawabe, Yoshiaki Itaya, Ippei Fujimori

Research output: Contribution to journalArticlepeer-review


Eight patients—5 with acute pneumonia. 1 with chronic bronchitis. 1 with infected bronchiectasis and 1 with acute pyelonephritis due to Escherichia coli-were given 2 g of cefodizime (THR-221), a newly developed cephalosporin antibiotic, b.i.d. intravenously for periods ranging from 8.5∼15.5 days. Of the 5 patients with pneumonia, 4 were successfully treated, but 1 needed further treatment with piperacillin. Sputum culture of 1 of the 4 successfully treated patients revealed Streptococcus pneumoniae. No significant side-effects were observed. Transient elevation of S-GOT, S-GPT, Al-P and γ-GTP was observed in one patient.

Original languageEnglish
Pages (from-to)400-404
Number of pages5
Publication statusPublished - 1988
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Cefodizime (THR-221) in the field of internal medicine'. Together they form a unique fingerprint.

Cite this